High-density oligonucleotide arrays were used to determine the sequence of the protease (PR) and reverse transcriptase (RT) genes of human immunodeficiency virus type 1 isolates from 35 patients in whom combination therapy that included a protease inhibitor had failed. Isolates had a median of three PR mutations (range, none to six). Three isolates had no known resistance mutations in PR. Twelve isolates (34%) had two or fewer resistance mutations in PR. The most commonly observed PR mutations were L10I, V82A/T/F, and L90M. No mutations were observed at codons 30 or 48. Mutations at RT codons 215 and 184 were observed in the majority of isolates. These data suggest that therapy can fail in some patients with relatively few PR resistance mutations. Clinical failure in the absence of resistance mutations implies inadequate drug exposure due to pharmacologic factors or suboptimal patient adherence to drug therapy.
such therapies, the population consensus sequence of HIV-1 PR and RT genes was determined for HIV-1 isolates from 35 patients in whom combination antiretroviral therapy that included a protease inhibitor had failed.
Methods
Study population and specimen collection. Subjects were HIVinfected persons from the Denver metropolitan area in whom combination therapy with a protease inhibitor was failing. Treatment failure was defined as a rising plasma HIV-1 RNA level or a plasma HIV-1 RNA level 110,000 copies/mL in the setting of apparent adherence to prescribed treatment. Isolation and cryopreservation of patients' plasma and peripheral blood mononuclear cells for HIV-1 culture were done according to standard consensus protocols [9] .
Nucleic acid sequencing and analysis. Nucleotide sequence data were obtained from proviral DNA of cultured HIV-infected peripheral blood mononuclear cells [9] or from plasma HIV RNA that was amplified by an RT-coupled polymerase chain reaction [10] . Hybridization-based nucleic acid sequencing was done with high-density oligonucleotide arrays as described [10] . This method is biased toward the detection of the predominant sequence in the virus population. The resulting nucleotide sequences were determined by use of the Genechip "rules" algorithm (Affymetrix, Santa Clara, CA) and were compared with the HIV-1 clade B consensus [11] . Additional sequence comparisons were made with a pairwise distance matrix (PAUP, version 3.1). Drug resistance mutations in PR and RT included for analysis were obtained from published reports [6] [7] [8] . The sequences have been submitted to GenBank (NCBI reference no. 444508; accession nos. AF072936-AF072974). Codon   8  10  37  46  47  50  54  62  63  64  71  82  84  90  93   Clade B consensus  NA  NA  R  L  N  M  I  I  I  I  P  I  A  V  I  L  I  1  Culture  IDV  ---I  ----L  --A  ---2  Culture  IDV, RTV, SQV  ------------V  M  -3  Culture  IDV  ------V  V  -L  -A  ---4 Plasma
NOTE. Amino acid residues are indicated by single-letter abbreviations. HIV-1 clade B consensus sequence [11] is shown for comparison. -indicates no change from consensus sequence; ? indicates indeterminate sequence. Protease inhibitor use: indinavir (IDV), ritonavir (RTV), saquinavir (SQV); slash indicates dual protease inhibitor use. NA, not applicable.
Results
Forty-seven patients were enrolled, but this analysis includes only the 35 patients for whom complete clinical data and treatment history were available. The median CD4 lymphocyte count was 157 cells/mm 3 (range, 5-515), and the median plasma HIV-1 RNA level was 5.0 log 10 copies/mL (range, 3.18-5.88). Patients had been treated with a median of two protease inhibitors (range, one to three). Thirty-four patients (97%) had received indinavir, 15 (43%) had received saquinavir, and 18 (51%) had received ritonavir. Two patients had received protease inhibitors in combination. None of the patients had received nelfinavir or amprenavir (141W94).
The nucleotide sequence of HIV-1 PR and RT genes was determined from cultured virus in 27 patients and from plasma virus in 11 patients. In 3 patients, sequencing was done on both cultured and plasma virus. To assess for the possibility of laboratory contamination, the nucleotide or amino acid sequences of virus isolates were compared with each other and with the sequences of 5 strains of HIV-1 commonly studied in our laboratory. The sequence difference between virus isolates from different patients or laboratory strains was ≥2.0%, consistent with a lack of contamination (data not shown). Drug resistance mutations in the PR gene were found in HIV-1 isolates from 32 of 35 patients (91%; table 1). The median number of PR resistance mutations per isolate was three (range, none to six). Virus isolates from 12 patients (34%) had two or fewer mutations in the PR gene. One patient had an isolate with only a single mutation in PR (N37S), and 3 patients had isolates with no known resistance mutations in PR.
The most commonly observed PR resistance mutations ). Of the 16 isolates with the L90M mutation, 12 (75%) also had mutations at codon 10 and/or 82. Whereas 10 (67%) of 15 isolates from patients with prior saquinavir therapy had an L90M mutation, this mutation was also found in 6 (30%) of 20 isolates from patients who were never treated with saquinavir. Mutations at codon 54 were found in 4 (11%) of 35 isolates and were always found in association with mutations at codon 82. No mutations were observed at codons 30 or 48. The I93L substitution previously noted as a naturally occurring polymorphism [10] was observed in 14 (40%) of 35 isolates.
Multiple mutations in RT were observed in patient isolates, with a median of four mutations per isolate (range, none to six; table 2). The distribution of RT resistance mutations reflected the patterns of antiretroviral therapy in the Denver metropolitan area. Thirty-four (97%) of 35 patients had isolates with one or more zidovudine resistance mutations (codons 41, 67, 70, 215, 219) [8] , and isolates from 28 patients (80%) had the M184V mutation, which confers resistance to zalcitabine [8] . One isolate (3%) had a didanosine resistance mutation at codon 74 [8] , and 4 (11%) had one or more nonnucleoside RT inhibitor resistance mutations (codons 103, 106, 108, 181, 188, 190) [8] . The multidrug resistance mutation at codon 151 was not observed.
Comparison of the sequences derived from plasma and cultured virus isolates in the same patient revealed limited differences. In 2 patients, these differences occurred at positions associated with protease inhibitor resistance (tables 1 and 2). Virus cultured from patient 4 showed an A71T substitution, but the plasma virus remained wild type at this position, whereas plasma virus from patient 26 had an L10I substitution, but the cultured virus remained wild type. Discordance between cultured and plasma virus was also observed in the RT sequence of patient 26. The M41L and T215Y substitutions were present in cultured virus but not in plasma virus.
Discussion
We have determined the population consensus sequence for HIV-1 PR and RT genes in HIV-1 isolates from 35 patients in whom combination antiretroviral therapy that included a protease inhibitor had failed. Although resistance mutations in PR and RT were common in patients with clinical failure of combination therapy, the number of PR mutations was lower than expected. These data suggest that treatment failure can be associated with relatively few PR mutations.
It is possible that those patients with protease inhibitor therapy failure who had two or fewer mutations may have had lower levels of drug exposure because of pharmacologic factors or poor adherence to their prescribed treatment regimen. Extragenic mutations, such as those at protease cleavage sites in the gag-pol precursor, may also be associated with protease inhibitor resistance [12] . The genetic analysis done in this study did not address this possibility.
Mutations at codon 90 were common, particularly in isolates from patients who were saquinavir-experienced. The L90M mutation also was detected in isolates from 4 saquinavir-naive patients treated with indinavir or ritonavir, usually in association with other PR resistance mutations (e.g., V82A/T/F or I84V). This finding suggests that L90M may contribute to failure of indinavir or ritonavir treatment. One implication of these results is that selection of the L90M substitution by saquinavir may impair the subsequent response to indinavir or ritonavir. In this regard, it is noteworthy that the virologic response to indinavir following long-term treatment with the hard gel capsule formulation of saquinavir was relatively modest, compared with the ≥2 log 10 reduction in plasma HIV-1 RNA level reported in protease inhibitor-naive subjects [4, 13] .
Fourteen of 35 isolates in this study carried a mutation at PR codon 93. Although the I93L substitution has been described as a naturally occurring polymorphism, the frequency of this substitution appears to be substantially higher in our treated population than in protease inhibitor-naive patients (40% vs. 20%) [10] .
Previous studies have shown that drug resistance mutations may be detected in plasma virus sooner than in cultured virus [2] . In the present study, the frequency of drug resistance mutations could have been underestimated, since many of the sequences were derived from cultured virus. However, plasma virus sequences from 4 patients also showed insignificant changes in PR (patients 5, 12, 38, 47), providing greater confidence in our results overall.
Population-based sequencing methods are limited by their inability to detect virus variants that are present at low frequencies in the population. These rare variants may have the potential to emerge rapidly as the predominant quasispecies in response to the appropriate selective pressure [6] . Although such variants might not have been detected by the methods used in our study, we do not believe that they can account for therapeutic failure in our patients. Given the rapid replication rate of HIV-1, the circulating virus population should be representative of the actively replicating population.
Four patients in our study had HIV-1 isolates with no known resistance mutations in the PR gene. Clinical failure in the absence of drug resistance implies inadequate drug exposure due to pharmacologic factors or suboptimal adherence to drug therapy. These results are qualitatively similar to those of another study in which nearly 50% of patients with protease inhibitor therapy failure had a wild type HIV-1 PR gene [14] . The different proportions of patients with wild type isolates in these two studies may reflect differences in patient adherence to drug regimens or differences in clinician assessment of adherence. An additional study of patients in whom PR inhibitor therapy failed revealed that genotypic evidence of resistance to each component of a multidrug regimen was not required for therapeutic failure [15] . Collectively, these studies make the point that not all treatment failure is due to viral drug resistance and reinforce the importance of assessing treatment adherence.
